Takeda Pharmaceutical Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Takeda Pharmaceutical Company Limited with three other
companies in this sector in Japan:
Eisai Company Limited
sales of 642.83 billion Japanese Yen [US$5.92 billion]
of which 88%
was Pharmaceutical Business),
Astellas Pharma Incorporated
(1.31 trillion Japanese Yen [US$12.03 billion]
of which 97%
was Sales of Pharmaceuticals), and
Daiichi Sankyo Company Limited
(929.72 billion Japanese Yen [US$8.56 billion]
of which 93%
was Prescription drugs).
Takeda Pharmaceutical Company Limited reported sales of ¥2.10 trillion (US$19.32 billion)
March of 2019.
increase of 18.5%
versus 2018, when the company's sales were ¥1.77 trillion.
Sales of Pharmaceutical Business saw an increase
19.6% in 2019, from
¥1.69 trillion to ¥2.03 trillion.
Not all segments of Takeda Pharmaceutical Company Limited experienced an increase in sales in 2019:
sales of Intellectual Property and Service Revenu fell 7.5% to ¥70.95 billion.
(However, this segment's sales were only a very small portion of the company's overall sales).